Deepcure
deepcure.com
Actively hiring
Prescription Drugs
Drug Discovery AI
Drug Discovery
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$64M
2 rounds on record
Latest round
$24M
Series A · Apr 2024 · 2 yr ago
Team
51-200
employees, estimated range
Backers
2
E14 Fund, TLV Partners
The money's age
Long since its last round
30 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 16, 2024
Raised a round Series A $24M · led by IAG Capital Partners · Pulse 2.0
Jan 4, 2023
Partnership Biosero and DeepCure Collaborate to Establish Fully Automated, AI-Powered Chemistry Synthesis Platform · Business Wire
Nov 8, 2021
Raised a round Series A $40M · CTECH - www.calcalistech.com
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Apr 2024 | $24M | IAG Capital Partners lead | Pulse 2.0 |
| Series A | Nov 2021 | $40M | — | CTECH - www.calcalistech.com |
Backed byfrom the funds' portfolios and accelerator catalogs
E14 Fund 
TLV Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Iambic Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, that uses physics-informed artificial…
Terray Therapeutics is a venture-backed biotechnology company that combines nanotechnology, experimental science, machine learning and…
Menten AI designs peptide therapeutics using computational protein design combined with quantum and classical optimisation. Founded in 2018…
Genesis Molecular AI is a drug discovery company headquartered in Burlingame, California, and founded in 2019. The company combines deep…
Iambic Therapeutics combines machine learning with automated chemistry to discover small molecule drugs. Its NeuralPLexer models predict…
Zymedi leverages ARS biology to discover novel therapeutics and first-in-class drugs for patients.
News
DeepCure Presents HyperCure Clinical Results at
DeepCure announced the results of the first-in-human (FIH) clinical trial for its next-generation hypertension treatment device, "HyperCure," at "Euro
Read more
Report
Peak XV Leads USD 25 Mn Round in Wealthtech Platform Stable Money
The round also saw participation from Z47, RTP Global, and Fundamentum Partnership.
Read more
Report
DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models
DeepCure, an immunology therapeutics company leveraging artificial intelligence (AI) to rapidly advance novel small molecule drugs, today announced the nomination of DC-15442 as its second development candidate. DC-15442 is a potent, selective, oral STAT6
Read more
Report
DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models
/PRNewswire/ -- DeepCure, an immunology therapeutics company leveraging artificial intelligence (AI) to rapidly advance novel small molecule drugs, today...
Read more
Report
DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models
/PRNewswire/ -- DeepCure, an immunology therapeutics company leveraging artificial intelligence (AI) to rapidly advance novel small molecule drugs, today...
Read more
Report
Deepcure Announces DC-15442 As Development Candidate, An Oral STAT6 Inhibitor With 100% In Vivo Inhibition Of Pstat6 And Comparable Efficacy To Dupilumab Across Disease Models
Read more
Report
DeepCure, Google and CWX Demonstrate the Potential For Chemistry LLMs To Increase Productivity In Medicinal Chemistry
DeepCure, a therapeutics company using AI to discover novel drugs for immune and inflammatory diseases, announced today the successful completion of a pilot
Read more
Report
Report
DeepCure Unveils STAT6 Inhibitor Program with Novel Oral Small Molecules Targeting Type 2 Inflammation
Read more
Report
DeepCure to Present In Vivo Data Showing Its Selective BRD4 (BD2) Inhibitor DC-9476 is Superior to Etanercept in Rheumatoid Arthritis
DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced it will present data showing its selective BRD4 (BD2) inhibitor DC-9476 is superior
Read more
Report
Show more news